AstraZeneca has halted a £200m expansion of its Cambridge research site, stalling its full £650m UK investment plan.
The project was expected to create 1,000 jobs and follows the scrapped £450m vaccine facility in Merseyside.
A spokesperson said the company continually reassesses investment needs and confirmed the Cambridge project is paused.
In contrast, AstraZeneca plans $50bn in US investments by 2030, including facilities in Virginia, Maryland, Massachusetts, California, Indiana, and Texas.
The pause follows a week of negative news for UK pharma, including Merck scrapping a £1bn London research centre.
Merck’s UK Discovery Centre was under construction and expected to employ 800 people before cancellation.
Sir John Bell warned major pharmaceutical companies are halting UK investments due to an uncompetitive environment.
Sanofi called for a clear Treasury plan, pausing UK investment until the life sciences sector becomes globally competitive.
Eli Lilly also put its £279m London lab project on hold amid uncertainty over UK regulations.
The industry urges NHS pricing reforms, including reducing the clawback rate from nearly 23% to single digits.
AstraZeneca Pauses £200m Cambridge Expansion Amid UK Pharma Setbacks
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
